Notícias e Atividades da Protara Therapeutics

Protara Therapeutics é uma empresa listada sob o símbolo TARA (US).

Veja o organograma con seus 22 executivos principais

Biografias mais buscadas da Protara Therapeutics

• Jesse Shefferman, Chief Executive Officer and Director
• Barry Flannelly, Director
• Jane Huang, Director

Recentes movimentos de executivos em Protara Therapeutics

• John Mcrae, ingressou na Companhia como Director, Clincal Operations  (Notícia publicada em 20 de abril de 2026).

Criar um alerta
para seguir os movimentos de executivos da Protara Therapeutics.

Protara Therapeutics possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Protara Therapeutics

• Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update | Protara Therapeutics, Inc.
• Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference | Protara Therapeutics, Inc.
• Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ | Protara Therapeutics, Inc.
• Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations | Protara Therapeutics, Inc.
• Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock – Protara Therapeutics, Inc.
• Press Releases – Protara Therapeutics, Inc.
• Press Releases – Protara Therapeutics, Inc.
• Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – Protara Therapeutics, Inc.
• Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations – Protara Therapeutics, Inc.
• Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors – Protara Therapeutics, Inc.
• View more press releases Close

Redes sociais sobre Protara Therapeutics

• Protara Therapeutics na Wikipedia, Google News e Yahoo Finance
• Protara Therapeutics na LinkedIn, X (Twitter) e YouTube